Pharmaceutical Benefits Scheme
Certain medications listed on the PBS are available only for specific therapeutic indications or to patients meeting specific criteria where the PBAC has deemed that the cost-benefit analysis is favourable only in those indications/patients. These are noted as "restricted benefits" on the Schedule. Medicare Australia places the onus of policing restricted benefits on the prescribers themselves and the pharmacists dispensing (unless the listing is also 'Authority Required'). For example, the COX-2 inhibitor celecoxib is listed on the PBS as a restricted benefit for the symptomatic treatment of osteoarthritis and rheumatoid arthritis. Prescribers using celecoxib for other indications are expected to indicate "non-PBS" on the prescription, and/or the pharmacist dispensing the celecoxib should charge the patient the full cost.
Eskatrol
In August 1970 the F.D.A. sought to limit the use of stimulants by calling for changes in labeling which decreased the number of allowable claims and intensified the warnings about possible hazards. F.D.A. Commissioner,
Charles C. Edwards, criticized the drug industry for not helping to prevent the abuse of amphetamines. Thomas M. Rauch, president of SmithKline & French laboratories, responded that his company had long promoted stricter drug abuse legislation and tighter controls
on production and distribution. SmithKline & French also made Dexedrine and Benzedrine. The F.D.A. began to restrict amphetamine manufacturer claims to only three medical uses, two of them uncommon. The two rare conditions specified were narcolepsy
and hyperactivity. The third permitted use was for suppressing appetite among persons who needed to lose weight. However, this would only be allowed for a total of a few weeks, and as a part of
treatment for obesity.